<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695224</url>
  </required_header>
  <id_info>
    <org_study_id>2018KYPJ126</org_study_id>
    <nct_id>NCT03695224</nct_id>
  </id_info>
  <brief_title>Matching Glaucoma With Impaired Cognition</brief_title>
  <acronym>MAGIC</acronym>
  <official_title>Association of Glaucoma Morbidity and Impairment of Topological Perception: a Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the leading cause of irreversible blindness in the world. The current study is&#xD;
      designed to find the underlying relationship between impairment of topological perception and&#xD;
      incidence of glaucoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma is currently the leading cause of irreversible blindness in the world. It has been a&#xD;
      difficult task for ophthalmologists and researchers to diagnose glaucoma, especially in early&#xD;
      stage. At present, glaucoma diagnosis mainly relies on OCT and visual field test, which have&#xD;
      relatively low sensitivity and specificity at the early stage of glaucoma. Previous studies&#xD;
      mainly focused on ocular manifestation of glaucoma. However, there was evidence that&#xD;
      abnormalities of visual pathway also existed in patients with glaucoma, indicating cerebral&#xD;
      cognitive defects may also be involved in glaucoma development. Thus, the current study was&#xD;
      designed, in which subjects at high-risk of developing glaucoma are separated into two group&#xD;
      based on test results of topological perception. After five years' follow-up, morbidity of&#xD;
      primary open-angle glaucoma would be compared between groups to see if there was any&#xD;
      relationship between impaired cognitive function and incidence of glaucoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 8, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morbidity of primary open-angle glaucoma</measure>
    <time_frame>From October 2018 to September 2024</time_frame>
    <description>Incidence of primary open angle glaucoma in the study subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in biometric parameters of optic nerve and macular region</measure>
    <time_frame>From October 2018 to September 2024</time_frame>
    <description>Biometric parameters of optic nerve include retinal nerve fiber layer (RNFL) thickness, ganglion cell layer (GCL) thickness, ganglion cell complex (GCC) thickness, etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visual field</measure>
    <time_frame>From October 2018 to September 2024</time_frame>
    <description>Mean Deviation (MD value)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Morbidity of Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Subjects with normal topological perception</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Subjects with abnormal topological perception</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Topological perception test</intervention_name>
    <description>Participants' topological perception are tested with self-designed devices. Participants are asked to respond to the figures shown on the screen, and a final score will appear after they finish all the questions.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10 ml of whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from communities in Guangzhou and nearby cities. Subjects&#xD;
        fulfilling the above eligibility criteria will be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged between 18-55;&#xD;
&#xD;
          2. Best corrected visual acuity ≥ 0.6, capable of completing routine glaucoma&#xD;
             examinations;&#xD;
&#xD;
          3. Spherical equivalent &lt; 3D；&#xD;
&#xD;
          4. No history of other ocular diseases (except mild cataract), including diabetic&#xD;
             retinopathy, age-related macular degeneration, optical neuropathy, eye trauma,&#xD;
             strabismus, nystagmus, severe dry eye, ptosis of the eyelid, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to sign informed consent, or cannot comply with the study protocol&#xD;
&#xD;
          2. Diagnosed with any kind of glaucoma (based on visual field and OCT, etc) or primary&#xD;
             angle-closure diseases(primary angle closure suspect and primary angle closure, based&#xD;
             on gonioscopy and UBM examination);&#xD;
&#xD;
          3. History of ocular surgeries or laser;&#xD;
&#xD;
          4. Diagnosed with specific neurologic diseases or psychiatric disorders: Parkinson's&#xD;
             disease, Alzheimer's disease, anxiety, depression, schizophrenia, etc.(based on scale&#xD;
             screening)&#xD;
&#xD;
          5. With severe systemic diseases: diabetes mellitus, hypertension(systolic&#xD;
             pressure≥160mmHg or diastolic pressure≥100mmHg ), heart diseases, kidney diseases,&#xD;
             rheumatological disorder, digestive diseases, cancer, etc.&#xD;
&#xD;
          6. Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2018</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xiulan Zhang</investigator_full_name>
    <investigator_title>Director of Clinical Research Center</investigator_title>
  </responsible_party>
  <keyword>Topological perception</keyword>
  <keyword>Glaucoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

